Tamura, Kei
Fujiyuki, Tomoko
Moritoh, Kanako
Akimoto, Hayato
Iizuka, Keigo
Sato, Hiroki
Asano, Kazushi
Yoneda, Misako
Kai, Chieko
Funding for this research was provided by:
Health and Labour Sciences Research Grants (15ck0106001h0003)
Japan Agency for Medical Research and Development (19ck0106281h0003)
Article History
Received: 26 October 2022
Accepted: 7 September 2023
First Online: 24 October 2023
Competing interests
: CK and MY are stockholders in rVirogen, Inc., which is a venture company established with the aim to develop oncolytic virotherapy with rMV-SLAMblind. The other authors declare no competing interests.